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OBJECTIVES: Treatment-resistant depression (TRD)
occurs in 10%–20% of all diagnosed cases of major
depression. There are currently no speciﬁc codes to 
identify TRD in administrative databases. The objectives
of this study were to: (1) apply an algorithm to identify
TRD-likely patients among a population of Saskatchewan
Health (SH) recipients who had a claim with a depression
diagnosis and at least one antidepressant prescription
between January 1, 1993 and December 31, 1995; (2)
determine the prevalence of TRD in this population; and
(3) assess differences in costs and resource utilization for
TRD-likely versus TRD-unlikely patients.
METHODS: A TRD-likelihood algorithm based on anti-
depressant switches, titrations and augmentation therapy
was applied in a SH claims sample of 13,533 pharmaco-
logically treated depressed patients to determine which
were likely to have TRD. Comparisons between the TRD-
likely and TRD-unlikely groups in resource utilization
and annualized costs were made using Wilcoxon tests for
continuous variables and chi-square tests for categorical
variables.
RESULTS: 863 patients (6.4%) were identiﬁed as TRD-
likely. TRD-likely patients had signiﬁcantly higher costs
and resource utilization compared to the TRD-unlikely
patients for all measured outcomes. Median annualized
costs per patient for hospital, physician and prescription
services were CAD$1403 for TRD-likely and CAD$548
for TRD-unlikely (p < .0001). The median number 
of health claims per patient was 51 for TRD-likely 
compared to 27 for TRD-unlikely (p < .0001). TRD-likely
patients had more physician visits (p < .0001) and hospi-
tal admissions (p < .0001) and had a longer median length
of stay (8 days vs. 4 days, p < .0001).
CONCLUSION: Patients who have TRD consume 
signiﬁcantly more medical resources and have higher
medical costs associated with their treatment than non-
TRD patients. Additional research is needed to under-
stand the biological and behavioral differences between
these populations. Successful management of this sub-
population of depressed patients may reduce treatment
costs and resource consumption for depression.
PMH16
PREVALENCE AND COSTS OF ACCIDENTS
AMONG ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER PATIENTS
Swensen A1, Birnbaum H2, Ben-Hamadi R2, Greenberg P2,
Cremieux PY2
1Eli Lilly and Company, Indianapolis, IN, USA; 2Analysis
Group/Economics, Cambridge, MA, USA
OBJECTIVES: This study investigates the impact of
Attention-Deﬁcit/Hyperactivity Disorder (“ADHD”) on
the prevalence and costs of accidents. The unique contri-
bution of this research is that it estimates a model that
predicts the probability of having an accident for indi-
viduals with and without ADHD.
METHODS: Administrative claims data from a large
employer (n > 100,000) were analyzed. ADHD patients
were identiﬁed as beneﬁciaries with one or more claims
for ADHD in the study period (1996–98). The ADHD
patient sample was compared to a matched control
sample. In addition to descriptive analysis, multivariate
analysis involving logistic regression was used to estimate
a model of the probability of having an accident.
RESULTS: ADHD patients have a greater incidence of
accidents than their controls (32% v. 20%). However,
given that a patient has an accident, the average number
of accident claims is the same between both groups (3.6
v. 3.5). Accident speciﬁc costs are greater for ADHD
patients than controls ($209 vs. $131) because patients
with this condition are more likely to have accidents.
Among patients with accident claims, ADHD patients
and controls had statistically similar costs. The multi-
variate analysis conﬁrms the utilization patterns found in
the descriptive analysis. The odds of having an accident
for ADHD patients are 1.7 times as great as that for con-
trols after taking account of all the other variables.
CONCLUSIONS: ADHD is a signiﬁcant predictor of
having an accident. However, given that a person has an
accident, ADHD patients generally have a similar number
of accident claims and costs as their controls.
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OBJECTIVE: To evaluate persistency with various
antipsychotic monotherapies and whether improved per-
sistency translates into cost savings.
METHODS: We use longitudinal claims data from 180
MCOs to identify 220 quetiapine patients who were new
to therapy and initiated on monotherapy between
October 1, 1997 and March 31, 1999 and tracked
through June 2000. Matched patients were randomly
selected to populate three comparator groups: haloperi-
dol, risperidone, and olanzapine. Primary endpoint was
the duration on monotherapy. Secondary endpoint was
whether costs decreased with greater duration on
monotherapy. Psychiatric related costs were also aggre-
gated by type of service. Analyses consisted of Cox 
proportional hazard models for time on monotherapy
and linear regressions for cost. Three subset analyses were
performed: patients aged 45 to 64, psychotic patients 65
or older, and patients with bipolar disorder.
RESULTS: For psychotic patients 45 to 64 years old, que-
tiapine-treated patients remained on treatment for 284
days vs. 261 days for risperidone (P = 0.71), 284 vs. 144
for haloperidol (P < 0.01), and 284 vs. 147 for olanzap-
ine (P < 0.01). Corresponding cost savings for this age
